Donna, a long-time Huntington Beach resident, shares her journey living with non-small cell lung cancer (NSCLC). Diagnosed with the rare ERBB2 exon 20 mutation, she recounts the initial…
This video features a presentation at the Best of Lung 2023 conference. Jaime Schneider, MD discusses the latest advancements in targeted therapies for lung cancer. They highlight the…
Julia Rotow, MD, medical oncologist at Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, reviews new treatment options for non-small cell lung cancer (NSCLC) patients. Dr. Rotow…
Rogerio C. Lilenbaum, MD, director of the Banner MD Anderson Cancer Center, discusses the ways physicians practicing in different care institutions order molecular panels for patients with nonsquamous…
Nathan A. Pennell, MD, PhD, director of the Lung Cancer Medical Oncology Program at Taussig Cancer Institute at the Cleveland Clinic, emphasizes the importance of molecular testing before…
In this video interview, Jonathan W. Goldman, MD, a health sciences clinical instructor in the Department of Medicine at the Jonsson Comprehensive Cancer Center Signal Transduction and Therapeutics…
In this video, Hatim Husain, MD, medical oncologist and associate professor of medicine for Moores Cancer Center at UCSD, explores how liquid biopsies are being incorporated into studies…
There has been an explosion of new data from targeted therapy studies since the 2017 publication of ASCO’s full clinical practice guidelines regarding systemic therapy for patients with…
Terence T. Sio, MD, MS, associate professor of radiation oncology at the Mayo Clinic and specialist in both X-ray-based and proton radiotherapies, discusses study results comparing the efficacy…
Long-term data from the KEYNOTE-010 trial showed that 35% of over 1,000 patients with non-small cell lung cancer (NSCLC) who had progressed on chemotherapy and were then treated…
The Oncologic Drugs Advisory Committee (ODAC) voted 6–5 that combining ramucirumab combined with established first-line EGFR-directed therapy had a favorable risk-benefit profile for patients with metastatic EGFR-mutant non-small…
In this double interview, Ross Camidge, MD, PhD, of the University of Colorado Cancer Center, and Lyudmila A. Bazhenova, MD, of UC San Diego Health, provide insights into…
